Putative fat fighter hits the middle man.
In this issue, Kamisuki and colleagues characterize fatostatin. This compound inhibits the activity of SREBPs, the master transcription factors of lipid homeostasis. This useful laboratory tool also improved the lipid profile of obese mice; does this have clinical implications?
Krycer
James Robert
JR
University of New South Wales, Sydney, Australia.
Brown
Andrew John
AJ
D000818:Animals; D005227:Fatty Acids / Q000096:biosynthesis* / Q000378:metabolism; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism; D008565:Membrane Proteins / Q000378:metabolism; D051379:Mice; D011485:Protein Binding; D051779:Sterol Regulatory Element Binding Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D013844:Thiazoles / Q000494:pharmacology*; D014158:Transcription, Genetic
D005227:Fatty Acids; D047908:Intracellular Signaling Peptides and Proteins; D008565:Membrane Proteins; C102196:SREBP cleavage-activating protein; D051779:Sterol Regulatory Element Binding Proteins; D013844:Thiazoles